Back to Journals » Therapeutics and Clinical Risk Management » Volume 2 » Issue 1

Differences between the bisphosphonates for the prevention and treatment of osteoporosis

Authors Andrew Grey, Ian R Reid

Published 15 March 2006 Volume 2006:2(1) Pages 77—86

Andrew Grey, Ian R Reid

Department of Medicine, University of Auckland, Auckland, NZ

Abstract: Bisphosphonates, pyrophosphate analogs which potently inhibit osteoclastic bone resorption, are now firmly established as first-line therapy for osteoporosis. Several bisphosphonates of varying antiresorptive potency are either in clinical use or well advanced in clinical trials. Alendronate and risedronate are agents of choice at present because data from randomized controlled trials demonstrate that each of these nitrogen (N)-containing bisphosphonates reduces the incidence of vertebral and nonvertebral fractures by about 50%, whereas evidence for antifracture efficacy is limited to the vertebral site currently for other bisphosphonates such as etidronate and ibandronate. There have not been direct studies comparing the antifracture efficacy of alendronate with that of risedronate. Intermittent administration of bisphosphonates is now a well established clinical practice, and the potent bisphosphonate zoledronate produces suppression of bone resorption for at least 12 months after a single intravenous dose. Future research will better define how to optimally administer these agents to maximize efficacy and patient compliance. The place in osteoporosis therapeutics of combining bisphosphonate therapy with agents that primarily stimulate bone formation, such as parathyroid hormone, remains to be defined.


Keywords: osteoporosis, fracture, bisphosphonates, bone resorption

Download Article [PDF] 

Readers of this article also read:

A case of mitochondrial cardiomyopathy with restrictive transmitral filling pattern

Otsui K, Inoue N, Tamagawa A, Onishi K

International Medical Case Reports Journal 2012, 5:19-22

Published Date: 13 April 2012

Treatment of gastrointestinal stromal tumor: focus on imatinib mesylate

Omar S Din, Penella J Woll

Therapeutics and Clinical Risk Management 2008, 4:149-162

Published Date: 8 February 2008

Optimal timing for antihypertensive dosing: focus on valsartan

Ramón C Hermida, Diana E Ayala, Carlos Calvo

Therapeutics and Clinical Risk Management 2007, 3:119-131

Published Date: 15 March 2007

Adalimumab in the treatment of arthritis

Philip J Mease

Therapeutics and Clinical Risk Management 2007, 3:133-148

Published Date: 15 March 2007

Hypokalemia secondary to capecitabine: a hidden toxicity?

Muhammad Wasif Saif, Mohammad Houman Fekrazad, Leslie Ledbetter, Robert B Diasio

Therapeutics and Clinical Risk Management 2007, 3:177-180

Published Date: 15 March 2007

Renal cell carcinoma and the use of sorafenib

James MG Larkin, Tim Eisen

Therapeutics and Clinical Risk Management 2006, 2:87-98

Published Date: 15 March 2006